Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jan;175(2):165-167.
doi: 10.1111/bph.14081.

Inventing new therapies without reinventing the wheel: the power of drug repurposing

Andreas Papapetropoulos  1   2 , Csaba Szabo  3
Affiliations
Editorial

Inventing new therapies without reinventing the wheel: the power of drug repurposing

Andreas Papapetropoulos et al. Br J Pharmacol. 2018 Jan.

Abstract

This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.

PubMed Disclaimer

References

    1. Ahmad A, Olah G, Herndon DN, Szabo C (2018). The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third‐degree burn injury. Br J Pharmacol 175: 232–245. - PMC - PubMed
    1. Barratt MJ, Frail DE. (eds) (2012). Drug repositioning: bringing new life to shelved assets and existing drugs. John Wiley & Sons, Hoboken, NJ.
    1. Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS et al (2018). Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases. Br J Pharmacol 175: 192–222. - PMC - PubMed
    1. Bertolini F, Sukhatme VP, Bouche G (2015). Drug repurposing in oncology – patient and health systems opportunities. Nat Rev Clin Oncol 12: 732–742. - PubMed
    1. Bombardo M, Malagola E, Chen R, Rudnicka A, Graf R, Sonda S (2018). Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation. Br J Pharmacol 175: 335–347. - PMC - PubMed

Publication types

LinkOut - more resources